ArticleThoracic cancer2022

The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.

Yu Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.